Literature DB >> 24557705

Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases.

W L Tan1, W Y Huang1, B Yin1, J Xiong2, J S Wu3, D Y Geng4.   

Abstract

BACKGROUND AND
PURPOSE: IDH1 mutational status probably plays an important role in the predictive response for patients with astroglioma. This study explores whether DTI metrics are able to noninvasively detect IDH1 status in astrogliomas.
MATERIALS AND METHODS: The DTI data of 112 patients with pathologically proven astroglioma (including 25, 12, and 10 cases with IDH1 mutation and 11, 11, and 43 cases without mutation in grades II, III, and IV, respectively) were retrospectively reviewed. The maximal fractional anisotropy, minimal ADC, ratio of maximal fractional anisotropy, and ratio of minimal ADC in the tumor body were measured. In the same World Health Organization grading, the imaging parameters of patients with and without IDH1 R132H mutation were compared by means of optimal metrics for detecting mutations. Receiver operating characteristic curve analysis was performed.
RESULTS: The maximal fractional anisotropy and ratio of maximal fractional anisotropy values had statistical significance between patients with IDH1 R132H mutation and those without mutation in astrogliomas of grades II and III. The areas under the curve for maximal fractional anisotropy and ratio of maximal fractional anisotropy were both 0.92 in grade II and 0.80 and 0.82 in grade III. The minimal ADC value and ratio of minimal ADC value also demonstrated statistical significance between patients with mutation and those without mutation in all astroglioma grades. The areas under the curve for minimal ADC were 0.94 (II), 0.76 (III), and 0.66 (IV), and the areas under the curve for ratio of minimal ADC were 0.93 (II), 0.83 (III), and 0.70 (IV).
CONCLUSIONS: Fractional anisotropy and ADC from DTI can noninvasively detect IDH1 R132H mutation in astrogliomas.
© 2014 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24557705      PMCID: PMC7964529          DOI: 10.3174/ajnr.A3803

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  33 in total

1.  Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.

Authors:  Delphine Loussouarn; Anne-Gaëlle Le Loupp; Jean-Sébastien Frenel; François Leclair; Andreas Von Deimling; Maud Aumont; Stéphane Martin; Mario Campone; Marc G Denis
Journal:  Int J Oncol       Date:  2012-03-16       Impact factor: 5.650

2.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.

Authors:  Catherine L Nutt; D R Mani; Rebecca A Betensky; Pablo Tamayo; J Gregory Cairncross; Christine Ladd; Ute Pohl; Christian Hartmann; Margaret E McLaughlin; Tracy T Batchelor; Peter M Black; Andreas von Deimling; Scott L Pomeroy; Todd R Golub; David N Louis
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

3.  MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.

Authors:  Inas S Khayal; Scott R Vandenberg; Kenneth J Smith; Colleen P Cloyd; Susan M Chang; Soonmee Cha; Sarah J Nelson; Tracy R McKnight
Journal:  Neuro Oncol       Date:  2011-08-24       Impact factor: 12.300

4.  In the assessment of supratentorial glioma grade: the combined role of multivoxel proton MR spectroscopy and diffusion tensor imaging.

Authors:  Q-G Zou; H-B Xu; F Liu; W Guo; X-C Kong; Y Wu
Journal:  Clin Radiol       Date:  2011-06-12       Impact factor: 2.350

5.  Glioma grade assessment by using histogram analysis of diffusion tensor imaging-derived maps.

Authors:  András Jakab; Péter Molnár; Miklós Emri; Ervin Berényi
Journal:  Neuroradiology       Date:  2010-09-21       Impact factor: 2.804

6.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

7.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.

Authors:  David Capper; Matthias Simon; Claus-Dieter Langhans; Jürgen G Okun; Jörg C Tonn; Michael Weller; Andreas von Deimling; Christian Hartmann
Journal:  Int J Cancer       Date:  2011-11-02       Impact factor: 7.316

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  16 in total

1.  Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.

Authors:  Ji Xiong; Wenli Tan; Jianbo Wen; Jiawei Pan; Yin Wang; Jun Zhang; Daoying Geng
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

2.  Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.

Authors:  Min Kyoung Lee; Ji Eun Park; Youngheun Jo; Seo Young Park; Sang Joon Kim; Ho Sung Kim
Journal:  Eur Radiol       Date:  2019-08-24       Impact factor: 5.315

3.  Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Authors:  Zongfang Li; Wei Zhao; Bo He; Tong San Koh; Yanxi Li; Yizhen Zeng; Zhuo Zhang; Jingzhong Zhang; Zujun Hou
Journal:  Contrast Media Mol Imaging       Date:  2020-11-22       Impact factor: 3.161

4.  MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.

Authors:  Javier E Villanueva-Meyer; Matthew D Wood; Byung Se Choi; Marc C Mabray; Nicholas A Butowski; Tarik Tihan; Soonmee Cha
Journal:  AJR Am J Roentgenol       Date:  2017-12-20       Impact factor: 3.959

5.  Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.

Authors:  Z Xing; X Yang; D She; Y Lin; Y Zhang; D Cao
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-27       Impact factor: 3.825

6.  Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.

Authors:  Tingting Liu; Guang Cheng; Xiaowei Kang; Yibin Xi; Yuanqiang Zhu; Kai Wang; Chao Sun; Jing Ye; Ping Li; Hong Yin
Journal:  Neuroradiology       Date:  2018-05-18       Impact factor: 2.804

7.  Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status.

Authors:  Chae Jung Park; Yoon Seong Choi; Yae Won Park; Sung Soo Ahn; Seok-Gu Kang; Jong-Hee Chang; Se Hoon Kim; Seung-Koo Lee
Journal:  Neuroradiology       Date:  2019-12-09       Impact factor: 2.804

Review 8.  MRI biomarkers in neuro-oncology.

Authors:  Marion Smits
Journal:  Nat Rev Neurol       Date:  2021-06-20       Impact factor: 42.937

9.  Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.

Authors:  S C Thust; J A Maynard; M Benenati; S J Wastling; L Mancini; Z Jaunmuktane; S Brandner; H R Jäger
Journal:  AJNR Am J Neuroradiol       Date:  2021-01-07       Impact factor: 3.825

10.  Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging.

Authors:  Seunghyun Lee; Seung Hong Choi; Inseon Ryoo; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  J Neurooncol       Date:  2014-09-10       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.